Clinical Trials Logo

Filter by:
NCT ID: NCT06336434 Not yet recruiting - Pregnancy Clinical Trials

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Start date: September 24, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II, multicenter, open-label, non-randomized study with four groups to characterize the pharmacokinetics and safety of Cabotegravir (CAB) and Rilpivirine (RPV) long-acting injectable (LA) during pregnancy and postpartum among people with HIV-1 viral suppression and their infants.

NCT ID: NCT06336382 Recruiting - Clinical trials for Late Onset Schizophrenia

Tau Biomarkers in Late-onset Psychosis (LOP)

Start date: February 16, 2024
Phase:
Study type: Observational

Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.

NCT ID: NCT06336356 Recruiting - Clinical trials for Uncontrolled Hypertension

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

Start date: June 10, 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.

NCT ID: NCT06336343 Recruiting - Plaque Psoriasis Clinical Trials

Bimekizumab in Plaque Psoriasis

Start date: March 2024
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleukin IL-17A or 23.

NCT ID: NCT06336304 Recruiting - Clinical trials for Urinary Incontinence

NXT Post-Market Clinical Follow-up

Start date: June 18, 2024
Phase:
Study type: Observational

NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations

NCT ID: NCT06336291 Not yet recruiting - Glioblastoma Clinical Trials

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

GLIOSTELLA
Start date: June 2024
Phase: Phase 2
Study type: Interventional

The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence

NCT ID: NCT06336122 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

OASIS: Peer Support for T2DM in Appalachia (Peer Participant)

OASIS
Start date: February 21, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? If effective, which facets of the peer model are most effective? Peer coaches will Undergo peer coach training. Reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting. Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.

NCT ID: NCT06336096 Recruiting - Pain Clinical Trials

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Start date: March 28, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ; VX-548) and its metabolite along with its safety and tolerability, in healthy participants.

NCT ID: NCT06336018 Recruiting - Liver Diseases Clinical Trials

A Research Study on Etavopivat in Participants With and Without Liver Disease

Start date: June 4, 2024
Phase: Phase 1
Study type: Interventional

The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.

NCT ID: NCT06335966 Recruiting - Esophageal Cancer Clinical Trials

BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy

BEST-RPP
Start date: January 25, 2024
Phase:
Study type: Observational

Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy. The BEST-RPP study aims to evaluate the acceptability and feasibility of using this novel approach to screen for Barrett's Esophagus (BE) and Esophageal Carcinoma (EAC) in rural primary care clinic settings in Oregon.